Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DRB10401 and HLA-DRB10408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.

American journal of human genetics - 1 Aug 2008

Hoffmann Steve, Cepok Sabine, Grummel Verena, Lehmann-Horn Klaus, Hackermüller Jörg, Hackermueller Jörg, Stadler Peter F, Hartung Hans-Peter, Berthele Achim, Deisenhammer Florian, Wassmuth Ralf, Wasmuth Ralf, Hemmer Bernhard

Abstract excerpt

The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-re...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation

Share to HLA Antigens

Share to HLA-DR Antigens

Share to HLA-DRB1 Chains

Share to Interferon-beta

Share to Multiple Sclerosis

Source

Open in PubMed Open full text

Identifiers

PMID: 18656179
DOI: 10.1016/j.ajhg.2008.07.006
PMCID: PMC2495071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18656179-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.PMID 18656179Read ↗

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.Semantic proximity Read ↗

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read ↗

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.Semantic proximity Read ↗

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Semantic proximity Read ↗

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaSemantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple SclerosisSemantic proximity Read ↗

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity Read ↗

HLA class I peptide polymorphisms contribute to class II DQβ0603:DQα0103 antibody specificitySemantic proximity Read ↗

Five commercially-available antibodies react differentially with allelic forms of human HLA-DR beta chain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.